| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cumulative months of treatment exposure | 2343 | 2200 | |
| Pneumocystis pneumonia, n (%) | 0 (0) | 4 (5.8) | .04 |
| Cryptococcus neoformans infection n (%) | 0 (0) | 1 (1.4) | .31 |
| Aspergillosis, n (%) | 0 (0) | 1 (1.4) | .31 |
| Varicella zoster, n (%) | 1 (1.4) | 5 (7.2) | .07 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| CMV disease, n (%) | 0 (0) | 3 (4.3) | .08 |
| Total OPIs, n (%) OPIs/month of exposure OPI/100 person-years | 2 (2.9) .0001 1.0 | 14 (20.3) .0006 7.6 | .0002 |
| OPI related deaths, n (%) | 1 (1.4) | 3 (4.3) | .10 |
| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cumulative months of treatment exposure | 2343 | 2200 | |
| Pneumocystis pneumonia, n (%) | 0 (0) | 4 (5.8) | .04 |
| Cryptococcus neoformans infection n (%) | 0 (0) | 1 (1.4) | .31 |
| Aspergillosis, n (%) | 0 (0) | 1 (1.4) | .31 |
| Varicella zoster, n (%) | 1 (1.4) | 5 (7.2) | .07 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| CMV disease, n (%) | 0 (0) | 3 (4.3) | .08 |
| Total OPIs, n (%) OPIs/month of exposure OPI/100 person-years | 2 (2.9) .0001 1.0 | 14 (20.3) .0006 7.6 | .0002 |
| OPI related deaths, n (%) | 1 (1.4) | 3 (4.3) | .10 |
PTLD: posttransplant lymphoproliferative disease.
| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cumulative months of treatment exposure | 2343 | 2200 | |
| Pneumocystis pneumonia, n (%) | 0 (0) | 4 (5.8) | .04 |
| Cryptococcus neoformans infection n (%) | 0 (0) | 1 (1.4) | .31 |
| Aspergillosis, n (%) | 0 (0) | 1 (1.4) | .31 |
| Varicella zoster, n (%) | 1 (1.4) | 5 (7.2) | .07 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| CMV disease, n (%) | 0 (0) | 3 (4.3) | .08 |
| Total OPIs, n (%) OPIs/month of exposure OPI/100 person-years | 2 (2.9) .0001 1.0 | 14 (20.3) .0006 7.6 | .0002 |
| OPI related deaths, n (%) | 1 (1.4) | 3 (4.3) | .10 |
| Characteristics . | CNI group (n = 70) . | Belatacept group (n = 69) . | P-value . |
|---|---|---|---|
| Cumulative months of treatment exposure | 2343 | 2200 | |
| Pneumocystis pneumonia, n (%) | 0 (0) | 4 (5.8) | .04 |
| Cryptococcus neoformans infection n (%) | 0 (0) | 1 (1.4) | .31 |
| Aspergillosis, n (%) | 0 (0) | 1 (1.4) | .31 |
| Varicella zoster, n (%) | 1 (1.4) | 5 (7.2) | .07 |
| EBV-positive PTLD, n (%) | 1 (1.4) | 0 | .43 |
| CMV disease, n (%) | 0 (0) | 3 (4.3) | .08 |
| Total OPIs, n (%) OPIs/month of exposure OPI/100 person-years | 2 (2.9) .0001 1.0 | 14 (20.3) .0006 7.6 | .0002 |
| OPI related deaths, n (%) | 1 (1.4) | 3 (4.3) | .10 |
PTLD: posttransplant lymphoproliferative disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
